SCHEMBL7002574

SCHEMBL7002574

O=C(NCC1Cc2cccc3c(=O)[nH]c(=O)n(c23)C1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
CTSK P43235 1/20 0.44
HTR1A P08908 2/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40
HDAC3 O15379 2/20 0.40
HDAC4 P56524 2/20 0.40
HDAC1 Q13547 2/20 0.40
HDAC7 Q8WUI4 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC10 Q969S8 2/20 0.40
HDAC11 Q96DB2 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
HDAC9 Q9UKV0 2/20 0.40
HDAC5 Q9UQL6 2/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7004878 0.91 USP30 (0.42) HTR1AKDM4EDRD2DRD3HDAC3
Hydrochloric Acid SCHEMBL7001226 0.89 HDAC3 (0.41) HTR1ADRD2DRD3HDAC3HDAC4
SCHEMBL7003217 0.88 DRD2 (0.41) HTR1AKDM4EDRD2DRD3HDAC3
SCHEMBL7003016 0.88 THRB (0.42) HTR1AKDM4ENAMPT
SCHEMBL7004553 0.87 DRD2 (0.40) HTR1ADRD2DRD3HDAC3HDAC4
SCHEMBL7006730 0.87 KDM4E (0.44) HTR1AKDM4EDRD2DRD3NAMPT
SCHEMBL7005337 0.86 HTR1A (0.38) HTR1ADRD2DRD3CDK4CCND1
SCHEMBL7008105 0.86 MTNR1A (0.50) HTR1ADRD2DRD3CDK4CCND1
SCHEMBL7009570 0.86 ROCK2 (0.42) HTR1APKMCDK4CCND1CCNE2
SCHEMBL7005191 0.85 PARP1 (0.42) HTR1AKDM4EPKMDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 CTSL 1532/4885CTSB 1032/4885CTSK 729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.